A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy

Trial Profile

A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms FREEDOM-Ev
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 24 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
    • 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.
    • 14 Nov 2016 Planned number of patients changed from 610 to 850.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top